Biocon Biologics Secures PMDA Approval for Ustekinumab Biosimilar

Biocon Biologics has received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its biosimilar Ustekinumab, designed to compete with Johnson & Johnson's Stelara. This approval enables Biocon to market the biosimilar in Japan, targeting conditions such as psoriasis vulgaris and psoriatic arthritis. The company aims to enhance access to effective treatments in the region. This milestone marks a significant step for Biocon in expanding its global biosimilars portfolio, following similar approvals in other markets. The announcement was made on January 7, 2025. 

Source: Businessupturn